Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2010 May 13;24(3):182–186. doi: 10.1002/jcla.20379

Evaluation of the poly(ADP‐ribose) polymerase‐1 gene variants in Alzheimer's disease

Hsin‐Ping Liu 1,†, Wei‐Yong Lin 2,3,†, Bor‐Tsang Wu 4, Shu‐Hsiang Liu 5, Wen‐Fu Wang 6, Chon‐Haw Tsai 7,8, Chun‐Cheng Lee 3,4, Fuu‐Jen Tsai 3,5,9,✉
PMCID: PMC6647671  PMID: 20486200

Abstract

Amyloid peptide is thought to play a critical role in neuronal death in Alzheimer's disease (AD), most likely through oxidative stress. Free radical‐related injury leads to DNA breaks, which subsequently activates the repair enzyme poly(ADP‐ribose) polymerase‐1 (PARP‐1). In this study, the relationship between genetic variants situated at the PARP‐1 gene and AD development was investigated. We performed a case and control study from a Taiwanese population enrolled 120 AD patients and 111 healthy controls by using a polymerase chain reaction restriction fragment length polymorphism approach for two PARP‐1 exonic polymorphisms, 414C/T (rs1805404) and 2456T/C (rs1136410), corresponding to protein residues at positions 81Asp/Asp and762Val/Ala. There were no significant differences in allele or genotype frequencies for either PARP‐1 gene variant between the case and control groups; however, upon analysis of the haplotype distribution, four haplotypes (Hts) were identified. We found that the distributions of Ht3‐TT and Ht4‐CC were significantly associated with an increased risk of AD (P<0.0001), whereas the Ht1‐TC haplotype showed a protective effect for cases compared with the control group (P<0.05). These results reveal that the PARP‐1 gene is highly associated with AD susceptibility and might contribute to a critical mechanism that mediates cell survival or death as a response to cytotoxic stress. J. Clin. Lab. Anal. 24:182–186, 2010. © 2010 Wiley‐Liss, Inc.

Keywords: Alzheimer's disease, PARP‐1, polymorphism

REFERENCES

  • 1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245–4249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule‐associated protein tau. Proc Natl Acad Sci U S A 1988;85:4051–4055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N‐terminus of beta‐amyloid. Nat Genet 1992;1:345–347. [DOI] [PubMed] [Google Scholar]
  • 4. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early‐onset familial Alzheimer's disease. Nature 1995;375:754–760. [DOI] [PubMed] [Google Scholar]
  • 5. Steiner H, Romig H, Grim MG, et al. The biological and pathological function of the presenilin‐1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem 1999;274:7615–7618. [DOI] [PubMed] [Google Scholar]
  • 6. Niizuma K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 2009;109:133–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Kovacs GG, Kalev O, Budka H. Contribution of neuropathology to the understanding of human prion disease. Folia Neuropathol 2004;42:69–76. [PubMed] [Google Scholar]
  • 8. Reddy PH. Amyloid precursor protein‐mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 2006;96:1–13. [DOI] [PubMed] [Google Scholar]
  • 9. Smith MA, Hirai K, Hsiao K, Pappolla MA, et al. Amyloid‐beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998;70:2212–2215. [DOI] [PubMed] [Google Scholar]
  • 10. Schuessel K, Schafer S, Bayer TA, et al. Impaired Cu/Zn‐SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 2005;18:89–99. [DOI] [PubMed] [Google Scholar]
  • 11. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. Use‐dependent effects of amyloidogenic fragments of (beta)‐amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 2001;21:1327–1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. LaFerla FM, Green KN, Oddo S. Intracellular amyloid‐beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499–509. [DOI] [PubMed] [Google Scholar]
  • 13. Love S, Barber R, Wilcock GK. Increased poly(ADP‐ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 1999;122:247–253. [DOI] [PubMed] [Google Scholar]
  • 14. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882–893. [DOI] [PubMed] [Google Scholar]
  • 15. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post‐translational modification of poly(ADP‐ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 1995;20:405–411. [DOI] [PubMed] [Google Scholar]
  • 16. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP‐ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 1996;93:1753–1758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162–1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Weinfeld M, Chaudhry MA, D'Amours D, et al. Interaction of DNA‐dependent protein kinase and poly(ADP‐ribose) polymerase with radiation‐induced DNA strand breaks. Radiat Res 1997;148:22–28. [PubMed] [Google Scholar]
  • 20. Tulin A, Spradling A. Chromatin loosening by poly(ADP)‐ribose polymerase (PARP) at Drosophila puff loci. Science 2003;299:560–562. [DOI] [PubMed] [Google Scholar]
  • 21. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315–424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Koh DW, Dawson TM, Dawson VL. Poly(ADP‐ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci 2005;62:760–768. [DOI] [PubMed] [Google Scholar]
  • 23. Canan Koch SS, Thoresen LH, Tikhe JG, et al. Novel tricyclic poly(ADP‐ribose) polymerase‐1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X‐ray cocrystal structure. J Med Chem 2002;45:4961–4974. [DOI] [PubMed] [Google Scholar]
  • 24. Mucke L, Masliah E, Yu GQ, et al. High‐level neuronal expression of abeta 1‐42 in wild‐type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 2000;20:4050–4058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545–555. [DOI] [PubMed] [Google Scholar]
  • 26. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly(ADP‐ribose) synthetase in neurotoxicity. Science 1994;263:687–689. [DOI] [PubMed] [Google Scholar]
  • 27. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP‐ribose) polymerase‐1‐dependent cell death by apoptosis‐inducing factor. Science 2002;297:259–263. [DOI] [PubMed] [Google Scholar]
  • 28. Strosznajder JB, Jesko H, Strosznajder RP. Effect of amyloid beta peptide on poly(ADP‐ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochim Pol 2000;47:847–854. [PubMed] [Google Scholar]
  • 29. Kassner SS, Bonaterra GA, Kaiser E, et al. Novel systemic markers for patients with Alzheimer disease? —a pilot study. Curr Alzheimer Res 2008;5:358–366. [DOI] [PubMed] [Google Scholar]
  • 30. Dorszewska J, Florczak J, Rozycka A, Jaroszewska‐Kolecka J, Trzeciak WH, Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol 2005;24:786–794. [DOI] [PubMed] [Google Scholar]
  • 31. Manly KF. Reliability of statistical associations between genes and disease. Immunogenetics 2005;57:549–558. [DOI] [PubMed] [Google Scholar]
  • 32. Lockett KL, Hall MC, Xu J, et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004;64:6344–6348. [DOI] [PubMed] [Google Scholar]
  • 33. Wang XG, Wang ZQ, Tong WM, Shen Y. PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 2007;354:122–126. [DOI] [PubMed] [Google Scholar]
  • 34. Chiang FY, Wu CW, Hsiao PJ, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res 2008;14:5919–5924. [DOI] [PubMed] [Google Scholar]
  • 35. Hur JW, Sung YK, Shin HD, Park BL, Cheong HS, Bae SC. Poly(ADP‐ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus. Rheumatology (Oxford) 2006;45:711–717. [DOI] [PubMed] [Google Scholar]
  • 36. Infante J, Sanchez‐Juan P, Mateo I, et al. Poly (ADP‐ribose) polymerase‐1 (PARP‐1) genetic variants are protective against Parkinson's disease. J Neurol Sci 2007;256:68–70. [DOI] [PubMed] [Google Scholar]
  • 37. Infante J, Llorca J, Mateo I, et al. Interaction between poly(ADP‐ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement Geriatr Cogn Disord 2007;23:215–218. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES